Needham & Company Downgrades Allos Therapeutics (ALTH) to Hold; Modest Increases in FOLOTYN Sales Expected in 2011, as Company Executes Strategy

Go back to Needham & Company Downgrades Allos Therapeutics (ALTH) to Hold; Modest Increases in FOLOTYN Sales Expected in 2011, as Company Executes Strategy